TRLV Trulieve Cannabis Corp.
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 1754195 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.1%
TTM net income YoY-218.5%
TTM EPS YoY-245.5%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin60.6%
Operating margin-25.6%
Net margin-41.3%
FCF margin16.2%
EBITDA margin-16.1%
Returns
ROE-45.2%
ROA-17.7%
ROIC (approx.)-24.8%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets63.6%
Debt / equity0.25x
Current ratio5.52x
Interest coverage-5.25x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue6.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.18B | $1.19B |
| Cost of revenue | $470.01M | $470.75M |
| Gross profit | $711.17M | $715.75M |
| SG&A expense | $445.21M | $510.45M |
| Operating income | $143.50M | $97.78M |
| Interest expense | $63.45M | $62.19M |
| Pretax income | $91.47M | $42.71M |
| Income tax | $208.11M | $197.59M |
| Net income | -$116.38M | -$155.10M |
| EBITDA | $261.13M | $210.59M |
| EPS (basic) | -0.58 | -0.79 |
| EPS (diluted) | -0.58 | -0.79 |
| Weighted avg. shares (diluted) | 191.32M | 189.99M |
| Balance sheet | ||
| Cash & equivalents | $255.53M | $238.80M |
| Short-term investments | $0 | $60.39M |
| Receivables | $10.50M | $8.29M |
| Inventory | $242.30M | $231.37M |
| Current assets | $562.72M | $604.56M |
| PP&E, net | $670.44M | $716.05M |
| Goodwill | $483.90M | $483.90M |
| Intangibles | $798.37M | $859.48M |
| Total assets | $2.70B | $2.87B |
| Current liabilities | $126.94M | $138.49M |
| Long-term debt | $136.74M | $364.84M |
| Total debt | $136.74M | $364.84M |
| Total liabilities | $1.55B | $1.62B |
| Shareholders' equity | $1.16B | $1.26B |
| Net debt | -$118.79M | $126.03M |
| Shares outstanding | 192.31M | 191.01M |
| Cash flow statement | ||
| Operating cash flow | $272.82M | $271.48M |
| Capital expenditure | $44.19M | $122.60M |
| Free cash flow | $228.63M | $148.88M |
| Investing cash flow | $13.50M | -$206.62M |
| Financing cash flow | -$270.50M | -$33.44M |
| Depreciation & amortization | $117.63M | $112.81M |
| Stock-based compensation | $20.47M | $20.20M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.